PERIPHERAL ARTERIAL DISEASE

本合同是外周血淋巴细胞多中心初步研究的一部分。 动脉疾病 本临床试验的目的是评估 多因素治疗方法在患者中的可行性 外周动脉疾病 如果进行全面试验， 旨在评估这些干预措施在减少 外周动脉疾病患者的心血管死亡率 本研究的主要目的是：1）确定确切的类型 和剂量的药物组合，这将导致增加的 治疗组中的HDL-C水平和LDL-C的等效降低 治疗组和对照组中的水平：2）确定是否 临床适当剂量的抗氧化剂改变血浆脂质 PAD患者的过氧化物酶和氧化LDL水平; 3）测定 这些不同干预措施的药物相互作用和不良反应： 特别是，调脂和抗氧化药物对 华法林患者的凝血参数; 4）确定 识别、招募和随访PAD患者的可行性 来自各种医疗诊所（即，戒烟诊所，糖尿病 诊所、外周血管诊所）。 研究人群应 由600名PAD患者或约100名参与者组成， 六个临床中心。 此合同行为是为了 协调中心的努力。

This Contract is a part of a multicenter pilot study of peripheral arterial disease. The purpose of this clinical trial is to assess the feasibility of a multifactorial therapeutic approach in patients with peripheral arterial disease. The full-scale trial, if performed, is intended to assess the effect of these interventions in reducing cardiovascular mortality in patients with peripheral arterial disease. The primary objectives of the study are to: 1) determine the exact type and dosage of drug combination which would result in an increase in the HDL-C level in the treatment group and equivalent reductions in LDL-C level in the treatment and comparison groups: 2) determine if antioxidants in clinically appropriate doses alter plasma lipid peroxidase and oxidized LDL levels in patients with PAD; 3) determine the drug interactions and adverse effects of these various interventions: in particular, the effects of lipid-modifying and antioxidant drugs on coagulation parameters in patients on warfarin; 4) determine the feasibility of identifying, recruiting and following patients with PAD from a variety of medical clinics (i.e., stop smoking clinics, diabetic clinics, peripheral vascular clinics). The study population shall consist of 600 patients with PAD or approximately 100 participants in each of six Clinical Centers. This contract action is for the Coordinating Center effort.